Lin BioScience Receives US FDA Orphan Drug Status for LBS-008 for the Treatment of Stargardt Disease
SAN DIEGO--(BUSINESS WIRE)--Lin BioScience, a drug development company specializing in innovative therapies for oncology, ophthalmology and metabolic diseases, announced today that the US Food and Drug Administration (FDA) has granted orphan drug designation to LBS-008, a first-in-class oral therapy for the treatment of Stargardt Disease. Stargardt Disease is currently an untreatable inherited condition that causes permanent vision loss in children during childhood and adolescence. It is the mo